Company Overview
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Recent Developments
- Dec 2025 Revenue of $13.86M (-14.2% YoY); net profit $-79.62M.
- Trailing 12 Months Year-on-year growth — revenue -14.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -14.17% |
Stock Price Performance
| 1 Year: | +263.55% |
| 6 Months: | +159.33% |
| 3 Months: | +130.18% |
| 1 Month: | +4.29% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.20 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 27.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PYXS Pyxis Oncology, Inc. PHARMA | 3.89 | -2.78 | $324.46M | 0.00% | -119.93% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 16.15M | - | - | - | 0 | 2.82M | 0 | 11.04M | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 2.39M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 2.82M | 0 | 8.65M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 22.91M | 22.57M | 23.46M | 26.95M | 24.36M |
| Operating Income | - | - | -3.19M | -35.73M | -5.94M | -11.62M | -31.39M | -25.73M | -28.39M | -20.95M | -18.12M | -25.35M | -5.61M | -20.03M | -23.75M | - | -22.91M | -19.75M | -23.46M | -18.30M | -24.36M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.36M | -19.21M | -22.93M | -15.40M | -23.90M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -21.16M | -18.07M | -22.00M | -17.00M | -23.27M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 283.00K | 0 | 1.10M | - |
| Net Income | -1.96M | -3.10M | -3.19M | -36.83M | -8.15M | -14.18M | -31.38M | -25.56M | -27.67M | -19.24M | -15.90M | -23.05M | -3.26M | -17.30M | -21.20M | - | -21.16M | -18.35M | -22.00M | -18.11M | -23.27M |
| Diluted EPS | - | - | - | - | -5.54 | -8.96 | -0.97 | -0.79 | -0.85 | -0.54 | -0.41 | -0.56 | -0.06 | -0.29 | -0.35 | - | -0.35 | -0.30 | -0.35 | - | -0.37 |
| R&D Expense | - | - | 2.42M | 32.77M | 3.21M | 7.85M | 20.07M | 17.17M | 19.03M | 11.90M | 11.39M | 14.69M | 13.03M | 13.95M | 17.74M | - | 17.04M | 17.13M | 17.81M | - | 19.98M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 16.15M | 13.86M |
| Cost of Revenue | - | - | - | 0 | 475.00K | 2.39M |
| Gross Profit | - | - | - | 0 | 15.67M | 11.47M |
| Operating Expenses | - | - | 123.48M | 82.20M | 84.17M | 95.89M |
| Operating Income | -12.89M | - | -123.48M | -82.20M | -68.50M | -84.42M |
| EBITDA | - | - | -122.77M | -80.27M | -65.51M | -79.91M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | -120.72M | -73.79M | -79.50M | -78.23M |
| Tax Provision | - | - | - | 0 | -2.16M | 1.39M |
| Net Income | -12.83M | - | -120.72M | -73.79M | -77.33M | -79.62M |
| Diluted EPS | - | - | -3.65 | -1.85 | -1.32 | -1.28 |
| R&D Expense | 9.05M | 51.05M | 86.13M | 49.59M | 58.75M | 73.70M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 10.15M | - | 211.38M | 173.73M | 157.18M | 91.52M |
| Current Assets | - | - | - | 186.61M | 124.60M | 132.44M | 72.11M |
| Cash & Equivalents | - | 8.08M | - | 179.29M | 9.66M | 19.47M | 15.42M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 598.00K | 21.00K | 0 | 700.00K |
| Total Liabilities | - | 3.85M | - | 50.55M | 48.02M | 36.43M | 38.11M |
| Current Liabilities | - | 3.69M | - | 31.63M | 25.76M | 17.68M | 21.13M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 18.92M | 21.33M | 20.20M | 18.67M |
| Total Equity | -2.87M | -15.64M | - | 160.82M | 125.70M | 120.75M | 53.41M |
| Shares Outstanding | - | - | - | 34.96M | 44.75M | 59.97M | 62.69M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.08M | - | -89.33M | -70.71M | -57.67M | -63.50M |
| Investing Cash Flow | -1.48M | - | -6.40M | -104.85M | 8.15M | 58.86M |
| Financing Cash Flow | 35.00K | - | 183.00K | 5.93M | 59.33M | 594.00K |
| Capital Expenditure | -1.48M | - | -6.40M | -6.73M | -237.00K | -9.00K |
| Free Cash Flow | -11.57M | - | -95.73M | -77.44M | -57.91M | -63.51M |
| Net Change in Cash | - | - | -95.55M | -169.63M | 9.81M | -4.05M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 97.1% | 82.8% |
| Operating Margin % | - | - | - | - | -424.2% | -609.2% |
| Net Margin % | - | - | - | - | -478.9% | -574.5% |
| ROE % | 82.0% | - | -75.1% | -58.7% | -64.0% | -149.1% |
| ROCE % | -199.5% | - | -68.7% | -55.6% | -49.1% | -119.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | GordonMD Global Investments LP | 12.02% | 10.02M | $33.38M |
| 2 | Pfizer Inc | 8.43% | 7.03M | $23.42M |
| 3 | Laurion Capital Management, LP | 5.88% | 4.90M | $16.32M |
| 4 | Vanguard Capital Management LLC | 2.49% | 2.08M | $6.91M |
| 5 | Atle Fund Management AB | 1.16% | 966.46K | $3.22M |
| 6 | Blackrock Inc. | 1.04% | 867.93K | $2.89M |
| 7 | Palo Alto Investors Lp | 1.04% | 864.28K | $2.88M |
| 8 | Marshall Wace LLP | 1.00% | 830.54K | $2.77M |
| 9 | Renaissance Technologies, LLC | 0.93% | 772.23K | $2.57M |
| 10 | Geode Capital Management, LLC | 0.71% | 591.85K | $1.97M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PYXS
PYXS Stock Price, Quote & Chart - ChartMill
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5oOENVQ3p2eWtBcV84MTg2bS1SbmsxT3Y3S25sMzk4N1hXd2hyS1NvZ3VBMzJsNV9GNnloNll4aTJDYU4zVjNpbnVleU1NU0wxUmR4YUQzcVh4VTkzUVE0?oc=5" target="_blank">PYXS Stock Price, Quote & Chart</a>&nbs…
Pyxis names a CEO who previously ran a company bought for $1.9B - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNYnZaQWdKNGpuQi1LNTJxVmFnZkxUR3FwdE5EdXhXOU1lSEVySkpWQm5MRHpjLTJzdnlLLXQzRktDRTkxLXlxRWJZcEdzWjU1OEttWVlHMVl2Rl91aWV1RkR1Q3lvM2pHUVFYNDhpQU9HMDNtY3hOTWxUMG8yclZVbWJxd1pIQVVsZzFwOF…
Pyxis Oncology Appoints Thomas Civik CEO and Chairman as John Flavin Becomes Lead Independent Director - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxNdjhNazctUnEwUnVDdkZPenVMaVYzSGxRMXpwa2t5aXI2d3ZsRnFEQXBKeUtDRGdubzN5MnNsaE4tV2lUZHUyVUZnV1ZMbTJRYmx2NHV2bE5Jc25ZNUlQTFNGOGV5Y2xXWjg5T25KWk5RbzNwSlVsOFV3Sk1JSFczRU1Kb0dIVEhmUzJCQj…
Pyxis Oncology (PYXS) CEO receives 2.5M options at $3.89 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOLVRUaFBkNmphTkxDeE1vT2JmTTIxQURoV0s3dG44ejAydW9NcFFUejFYdkVlVHhxNFQyWUxTcTUxWDZqMHdrbGYxZ3MtaFE3eFAxMlM1ckNiM2RJM1BiUTV2bncxWENjeHpDVEJNeTFabGswZTZaZmlXYnFRZkdwaUtSa0tlQ3B0QVJpVW…
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOM1dHb0JnTklISE9ieE4zdkM4SEVhQXdEeW41RW5wVzE3WTh0eHIwYjY3SjZBUkVZbzRHVm1tbkY2dTJDUkdMaDVYLTZCNEF3elRIc0ZiOUZsRDJRZGdPcFRDTVdBVGFmNXhEOTVheTdEM2kxM2tvODVEekxLWUs0X1FfV0RUSnNxN3BYek…
PYXS Rallies As Pyxis Oncology Extends Cash Runway To 2027 - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTE00ZHVBVVBBRUkzemx1TTJKRmRWcUx6bnpuMmQtMVlSMTh3UTFlRmhDODBaQVBTQmo2OVVMby14anh0UVBudVZ5d1NoTHhwcmZ5YlA2RTduZmFGb2FTWWhWSFVyajZnNDRLcVVsTzFieTU0cTFlR2VfSHd6a3M?oc=5" target="_blank">…
PYXS — Frequently Asked Questions
What is the current share price of Pyxis Oncology, Inc. (PYXS)?
As of 2026-09-19 21:16 PDT, Pyxis Oncology, Inc. (PYXS) trades at $3.89 on NasdaqGS. Its 52-week range is $1.06 to $5.34.
What is the market capitalisation of PYXS?
Pyxis Oncology, Inc. (PYXS) has a market capitalisation of $324.46M on NasdaqGS.
What is the P/E ratio of PYXS?
PYXS trades at a trailing price-to-earnings (P/E) ratio of -2.78. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 18.50.
Is PYXS a good stock to buy?
This page provides a data-driven analysis of Pyxis Oncology, Inc. (PYXS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.